A guide to the effects of a large portion of the residues of triosephosphate isomerase on catalysis, stability, druggability, and human disease
Review
-
- Overview
-
- Research
-
- Identity
-
- Additional Document Info
-
- View All
-
Overview
abstract
-
Triosephosphate isomerase (TIM) is a ubiquitous enzyme, which appeared early in evolution. TIM is responsible for obtaining net ATP from glycolysis and producing an extra pyruvate molecule for each glucose molecule, under aerobic and anaerobic conditions. It is placed in a metabolic crossroad that allows a quick balance of the triose phosphate aldolase produced by glycolysis, and is also linked to lipid metabolism through the alternation of glycerol-3-phosphate and the pentose cycle. TIM is one of the most studied enzymes with more than 199 structures deposited in the PDB. The interest for this enzyme stems from the fact that it is involved in glycolysis, but also in aging, human diseases and metabolism. TIM has been a target in the search for chemical compounds against infectious diseases and is a model to study catalytic features. Until February 2017, 62%25 of all residues of the protein have been studied by mutagenesis and/or using other approaches. Here, we present a detailed and comprehensive recompilation of the reported effects on TIM catalysis, stability, druggability and human disease produced by each of the amino acids studied, contributing to a better understanding of the properties of this fundamental protein. The information reviewed here shows that the role of the noncatalytic residues depend on their molecular context, the delicate balance between the short and long-range interactions in concerted action determining the properties of the protein. Each protein should be regarded as a unique entity that has evolved to be functional in the organism to which it belongs. Proteins 2017; 85:1190–1211. © 2017 Wiley Periodicals, Inc. © 2017 Wiley Periodicals, Inc.
publication date
published in
Research
keywords
-
catalysis; druggability; human disease; mutation; stability; triosephosphate isomerase amino acid; triosephosphate isomerase; enzyme inhibitor; protein binding; triosephosphate isomerase; catalysis; drug design; enzyme stability; human; infection; nonhuman; priority journal; Review; amino acid sequence; antagonists and inhibitors; biocatalysis; chemistry; enzyme active site; enzyme specificity; enzyme stability; genetics; kinetics; metabolism; molecular model; protein domain; protein secondary structure; sequence alignment; sequence homology; site directed mutagenesis; structure activity relation; Amino Acid Sequence; Biocatalysis; Catalytic Domain; Enzyme Inhibitors; Enzyme Stability; Humans; Kinetics; Models, Molecular; Mutagenesis, Site-Directed; Protein Binding; Protein Interaction Domains and Motifs; Protein Structure, Secondary; Sequence Alignment; Sequence Homology, Amino Acid; Structure-Activity Relationship; Substrate Specificity; Triose-Phosphate Isomerase
Identity
Digital Object Identifier (DOI)
PubMed ID
Additional Document Info
start page
end page
volume
issue